Apogee Therapeutics Inc (APGE) PT Lowered to $116 at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts APGE Hot Sheet
Price: $135.07 --0%
Rating Summary:
5 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
5 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Deutsche Bank analyst David Hoang lowered the price target on Apogee Therapeutics Inc (NASDAQ: APGE) to $116.00 (from $118.00) while maintaining a Buy rating.
You May Also Be Interested In
- Wayfair (W) PT Raised to $160 at Truist Securities
- Livanova (LIVN) PT Raised to $120 at Jefferies
- Livanova (LIVN) PT Raised to $115 at Mizuho
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
